Inoviq Ltd (AU:IIQ) has released an update.
INOVIQ Ltd has successfully raised $9.4 million to enhance its proprietary exosome platform, which is making strides in cancer diagnostics and therapeutics, including a promising exosome therapy for targeting breast cancer and a test for ovarian cancer. The company is well-capitalized with a cash balance of $9.233 million as of June 30, 2024, and is expanding its technological applications to include Alzheimer’s Disease diagnostics. The recent capital infusion and product advancements have positioned INOVIQ to explore strategic mergers and acquisitions while advancing its research and development initiatives.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
